Comparative efficacy of Canagliflozin Versus Empagliflozin on oxidative stress – In-Vitro method
Abstract
Diabetes is characterized by hyperglycemia resulting from defects in insulin secretion, insulin action or both. Hyperglycemia causes auto-oxidation of glucose to form free radical .O2-. The production of free radicals beyond the limit of scavenging activity of endogenous antioxidant defenses result in micro vascular and macro vascular complications. In this study the antioxidant efficacy of Canagliflozin and Empagliflozin was compared by 1, 1-Diphenyl-2-Picrylhydrazyl radical scavenging activity (DPPH) assay and nitric oxide scavenging activity. Sodium-glucose co-transporter-2 inhibitors shows pleotrophic therapeutic potential in the treatment of type II Diabetes. On comparison with ascorbic acid both Canagliflozin and Empagliflozin shows antioxidant property. However empagliflozin has higher efficacy for reducing oxidative stress when compared with canagliflozin.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.